diltiazem has been researched along with indoramin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Acheson, AG; Scholefield, JH | 1 |
| Kaman, L; Medhi, B; Pandhi, P; Prakash, A; Prakash, O; Rao, RS | 1 |
2 review(s) available for diltiazem and indoramin
| Article | Year |
|---|---|
Pharmacological advancements in the treatment of chronic anal fissure.
Topics: Administration, Topical; Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Albuterol; Botulinum Toxins; Calcium Channel Blockers; Carbachol; Central Nervous System Agents; Cholinergic Agonists; Chronic Disease; Complementary Therapies; Diltiazem; Drug Administration Schedule; Fissure in Ano; Humans; Indoramin; Nitrates; Nitroglycerin; Randomized Controlled Trials as Topic | 2005 |
Recent advances in the pharmacotherapy of chronic anal fissure: an update.
Topics: Administration, Topical; Adrenergic alpha-Antagonists; Anal Canal; Botulinum Toxins; Calcium Channel Blockers; Chronic Disease; Clinical Trials as Topic; Diltiazem; Fissure in Ano; Headache; Humans; Indoramin; Injections, Intralesional; Lidocaine; Nifedipine; Nitroglycerin; Ointments | 2008 |
4 other study(ies) available for diltiazem and indoramin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |